Cerianna™ (fluoroestradiol F18) injection
At a glance
ER discordance in MBC
Detecting ER+ lesions
Unique mechanism of action
Concordance with biopsy
SEEING CLEARER
The only imaging agent that detects whole-body ER+ lesion status
Unique mechanism of action that detects ER+ lesions*†5
Verified concordance with biopsy for determining ER status in MBC* 1
Distinct mode of action that may help inform clinical decisions
F18 fluoroestradiol and FDG PET images in a MBC treatment responder and non-responder*†15

Patient 1 (anterior/superior) responded to treatment with an AI and a CDK 4/6 inhibitor*15

Patient 2 (anterior/superior) did not respond to treatment with an AI and a CDK 4/6 inhibitor*15
Potential clinical applications
Determine ER+ status in recurrent or metastatic lesions, as an adjunct to biopsy
Assess ER+ status in difficult-to-biopsy lesions
Evaluate extent of ER expression in indolent tumors
May resolve clinical dilemmas after inconclusive results from conventional assessment